World’s only 100% authentic bio-identical recombinant STGF

“Biotechnology means any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use.”

Genetic engineering is an important discipline of biotechnology and has a wide range of applications covering new drug developments, environmental conservation, energy generation and crop improvements yielding plants that could withstand various external insults. Through genetic engineering, a target (recombinant) protein could be produced efficiently using the machinery of the foster host. The engineered host may undergo fermentative cultivation to attain large quantities of the recombinant protein. Subsequent to purification to remove the contaminants, the recombinant protein is attainable as a highly pure, fully bioactive and authentic product.

Bacterial Expression Systems

1) Escherichia coli Excretion System

We have developed unique E. coli excretion systems using the Tac and LacUV5 cassettes, in conjunction with plasmid stabilizers for efficient production of recombinant proteins.

2) Bacillus subtilis Secretion System

Another expression & secretion system is engineered in B. subtilis for efficient extracellular production of heterologous proteins. Regulatory cassettes containing transcriptional controls derived from the veg I promoter and the Staphylococcal protein A signal peptide are employed in this system.

There are many advantages of the extracellular approach over the intracellular one for the production of recombinant proteins.

  • Correct folding to a functional native form – authentic and bioactive product
  • Reduction of proteolysis, and thus higher product yields
  • Reduction of contamination from unwanted proteins (e.g. endotoxin), and thus attainment of product with better quality
  • Unwanted N-terminal methionine can be avoided
  • Easy purification process and reduced production cost
  • Suitable for large and industrial scale production
  • Applicable for the production of all naturally secretory proteins
  • Applicable for the production of mildly toxic proteins
  • Continuous production possible

Patents List

Method and Composition for treating skin wounds with epidermal growth factor

  • Wong, W.K.R., Kwong, W. Y. (2016) Improved means and method for hyper-production of authentic hbFGF in E. coli. Hong Kong Patent Application submitted.
  • Wong, W.K.R. (2015, pending) Means and method for expression of authentic human epidermal growth factor and/or basic fibroblast growth factor in cytoplasm and/or culture medium of Escherichia coli. US Provisional Patent Application No.: 61/808.062; filed on 4 March 2013.
  • Wong, W.K.R. (2015) Means and methods for producing authentic human basic fibroblast growth factor. US Patent No.: 9,017,968 B2; Granted on 28 April 2015.
  • Wong, W.K.R., Lam, K.H.E. and Tsang, M.W. (2003). Method and composition for treating skin wounds with epidermal growth factor. March, PCT Patent Application No.: PCT/CN03/00178.
  • Wong, W.K.R., Lam, K.H.E. and Tsang, M.W. (2003). Method and composition for treating skin wounds with epidermal growth factor. March, Taiwanese Patent Application No.: 92105257.
  • Wong, W.K.R. and Lam, K.H.E. (2000). Bacterial expression system. US Patent: 6,146,848.
  • Wong, W.K. and Chan, W.K. (2000). Cellobiase obtained from Cellulomonas biazotea. HK Patent: HK1012679.
  • Wong, W.K. and Chan, W.K. (1998). Novel cellobiase enzyme. UK Patent: GB2 289 050 B.
  • Wong, W.K. (1998). Production of human interferon α1b as an excreted recombinant protein in E. coli. PRC Patent: 1186120.
  • Wong, W.K.R. and Sutherland, M. (1990-1997). Excretion of heterologous proteins from E. coli. Worldwide Patent: Patent numbers: US 5646015 A; EP 0357 391 B1; ES 2091197T3; DE 68926895; CA 1,332,813C; US 5,223,407A; JP 2177889A; EP 357391A.